Evan Warner, MD
Ophthalmology · Madison, WINPI 1700104346
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Alcon accounts for 60.4% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $78 and has fallen 79.6% since, to $16 in 2025. That places this record below the midpoint for ophthalmology clinicians in WI, where the typical reported total is $301.
Across 5 payments — averaging $41.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$125
- Bausch & Lomb Americas Inc.$78
- Biotissue Holdings Inc.$4
Across 9 payments — averaging $862.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$8K
What the payments were for
- Food & beverage$206100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 3 | $125 |
| Bausch & Lomb Americas Inc. | 1 | $78 |
| Biotissue Holdings Inc. | 1 | $4 |
How this compares
$206 in reported general payments places this provider in the 40th percentile of 337 ophthalmology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 23 | $25,981 |
| Fluorometholone | 223 | $15,950 |
| Prednisolone Acetate | 332 | $15,736 |
| Cyclosporine | 29 | $10,955 |
| Lotemax SmLoteprednol Etabonate | 22 | $5,365 |
| MoxifloxacinMoxifloxacin Hcl | 165 | $3,165 |
| ValacyclovirValacyclovir Hcl | 61 | $2,235 |
| Difluprednate | 17 | $1,669 |
| Latanoprost | 19 | $426 |
| ErythromycinErythromycin Base | 19 | $223 |
| Ofloxacin | 17 | $219 |
| Timolol Maleate | 12 | $112 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Madison
- Michael ShapiroMadison$71K
- Julia AgapovMadison$26K
- Neil FarbmanMadison$13K
- Eric WeinlanderMadison$9K
- Gordon CrabtreeMadison$8K
- Paul KaufmanMadison$6K
- Andrew ThliverisMadison$5K
- Shahed GhoghawalaMadison$4K
- Sina Rashidi KikanlooMadison$4K
- Suzanne van LandinghamMadison$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.